Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 5.88B | 5.78B | 6.03B | 6.79B | 6.34B | 4.97B |
Gross Profit | 1.07B | 1.15B | 1.31B | 1.62B | 1.38B | 1.07B |
EBITDA | 237.00M | 692.00M | 197.00M | 1.20B | 1.21B | 767.00M |
Net Income | -420.00M | 86.00M | -238.00M | 578.00M | 608.00M | 219.00M |
Balance Sheet | ||||||
Total Assets | 7.49B | 7.51B | 8.25B | 7.64B | 7.55B | 7.08B |
Cash, Cash Equivalents and Short-Term Investments | 502.00M | 713.00M | 1.20B | 1.10B | 1.45B | 1.10B |
Total Debt | 244.00M | 4.36B | 4.30B | 3.81B | 3.93B | 4.28B |
Total Liabilities | 7.25B | 6.91B | 7.51B | 6.53B | 6.47B | 6.27B |
Stockholders Equity | 237.00M | 604.00M | 737.00M | 1.11B | 1.08B | 813.00M |
Cash Flow | ||||||
Free Cash Flow | -35.00M | -993.00M | 186.00M | 447.00M | 543.00M | 540.00M |
Operating Cash Flow | 277.00M | -633.00M | 556.00M | 754.00M | 820.00M | 807.00M |
Investing Cash Flow | -310.00M | -353.00M | -229.00M | -284.00M | 220.00M | -234.00M |
Financing Cash Flow | -26.00M | -36.00M | 172.00M | -685.00M | -560.00M | -449.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Neutral | $3.13B | 26.46 | 5.09% | 3.16% | 3.28% | 1.69% | |
63 Neutral | $7.05B | 8.62 | 14.52% | 5.38% | 1.60% | -3.97% | |
58 Neutral | HK$16.52B | 4.18 | -4.93% | 4.58% | -5.74% | -81.55% | |
58 Neutral | $2.02B | 74.95 | 1.55% | 2.08% | -5.45% | -87.13% | |
57 Neutral | $3.18B | ― | -28.05% | 2.00% | -4.31% | -1421.83% | |
53 Neutral | $8.03B | ― | -8.66% | 2.39% | -33.05% | -97.63% | |
49 Neutral | $1.89B | 59.33 | -87.50% | 6.63% | -0.68% | ― |
On August 3, 2025, Chemours, Corteva, and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all pending environmental claims, including PFAS contamination, related to their operating sites and statewide issues. The settlement involves a $875 million payment over 25 years, with Chemours responsible for 50% of the payments. The agreement also includes mechanisms for future remediation funding and establishes a Reserve Fund for financial security. Additionally, Chemours entered into an agreement to sell its rights to $150 million in insurance proceeds related to PFAS claims to DuPont and Corteva.
The most recent analyst rating on (CC) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Chemours Company stock, see the CC Stock Forecast page.